nci-drsymposiumseries (Agenda)

Session 1: Monday, November 16

NCI Director’s Presentation
Norman Sharpless, M.D.
Director, National Cancer Institute

Welcome and Meeting Goals
Gordon Mills, M.D., Ph.D.
Oregon Health & Science University

Kevin Haigis, Ph.D.
Dana-Farber Cancer Institute

Session I: Combinatorial Therapy;
Chairperson: Gordon Mills, M.D., Ph.D, Oregon Health & Science University
(focus on approaches to design and implement combination therapies; 20 minutes for each presentation & 5 mins for Q&A)

Defining a cancer dependency map
William Hahn, M.D., Ph.D.
Dana-Farber Cancer Institute

Lineage Plasticity in Prostate Cancer
Charles Sawyers, M.D.
Memorial Sloan Kettering Cancer Center

Targeting drug resistance by regulatory-network based cell reprogramming
Andrea Califano, Ph.D.
Columbia University

Systematic characterizations of functionally-relevant mutational landscapes
Elizabeth Brunk, Ph.D.
University of California, San Diego

Modeling tumor heterogeneity towards personalized cancer medicine
Nataly Kravchenko-Balasha, Ph.D.
The Hebrew University of Jerusalem

Preview of upcoming next session

Session 2: Tuesday, November 17

Session II: Evolutionary Biology;
Chairperson: Shannon Hughes, Ph.D., Division of Cancer Biology, NCI
(focus on the dynamics of evolution to understand treatment resistance; 20 minutes for each presentation & 5 mins for Q&A)

Delineating the eco-evolutionary dynamics of tumor progression and resistance
Christina Curtis, Ph.D.
Stanford University

Evolutionary Therapy
Alexander (Sandy) Anderson, Ph.D.
Moffitt Cancer Center

Exploiting evolutionary steering to control drug resistance in cancer
Andrea Sottoriva, Ph.D.
The Institute of Cancer Research, UK

Invasion of homogeneous and polyploid populations in nutrient-limiting environments
Noemi Andor, Ph.D.
Moffitt Cancer Center

Single-cell lineage tracing and RNA-seq reveal the rates, routes, and drivers of metastasis in cancer xenografts
Jeffrey Quinn, Ph.D.
University of California, San Francisco

Preview of next session

Session 3: December 2, 2020

Session III: Tumor Ecosystem;
Chairperson: Kevin Haigis, Ph.D., Dana Farber Cancer Institute
(focus on the role of the tumor ecosystem in drug resistance and sensitivity; 20 minutes for each presentation & 5 mins for Q&A)

Characterization and targeting of tumor-associated macrophages in the melanoma tumor microenvironment
Kathryn Miller-Jensen, Ph.D.
Yale University

A unified atlas of CD8 T cell dysfunctional states in cancer and infection
Christina Leslie, Ph.D.
Memorial Sloan Kettering Cancer Center

Targeting tumor associated macrophages to promote anti-tumor immunity
Judith Varner, Ph.D.
University of California, San Diego

Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer
Jennifer Guerriero, Ph.D.
Harvard Medical School

An Integrated Clinical, Omic, and Image Atlas of an Evolving Metastatic Breast Cancer
Joe Gray, Ph.D.
Oregon Health & Science University

Preview of next session

Session 4: December 16, 2020

Session IV: Tumor Heterogeneity & Cell Plasticity I;
Chairperson: Jeff Hildesheim, Ph.D., Division of Cancer Biology, NCI
(role of heterogeneity in drug response and resistance, biological basis for cell plasticity and impact on response and resistance; 20 minutes for each presentation & 5 mins for Q&A)

A novel endocytic mechanism used for antigen uptake from live tumor to immune cells
Nina Serwas, Ph.D.
University of California, San Francisco

Single Cell Analysis of Treatment-Naïve versus Treatment-Refractory NSCLC Demonstrates Differential Enrichment of Partial Epithelial-Mesenchymal States
Sylvia Plevritis, Ph.D.
Stanford University

Interpreting the cancer genome through machine learning models of the cancer cell
Trey Ideker, Ph.D.
University of California, San Diego

Tumor stem cells arising from a non-stem origin maintain a differentiated phenotype and modulate T cell activity
Ken Lau, Ph.D.
Vanderbilt University

Heterogeneity and the beginnings of cancer
Arthur Lander, M.D., Ph.D.
University of California, Irvine

Preview of Next Session

Session 5: December 17, 2020

Session V: Tumor Heterogeneity & Cell Plasticity II;
Chairperson: Daniela Gerhard, Ph.D., Office of Cancer Genomics, NCI
(role of heterogeneity in drug response and resistance, biological basis for cell plasticity and impact on response and resistance; 20 minutes for each presentation & 5 mins for Q&A)

Decoding Enhancer Dynamics and Its Drivers in Breast Cancer metastasis and therapy resistance
Zhijie (Jason) Liu, Ph.D.
UT Health San Antonio

Single-cell pharmacogenomics targets an inflamed chemoresistant tumor subpopulation in triple negative breast cancer
Sourav Bandyopadhyay, Ph.D.
University of California, San Francisco

Cancer cell intrinsic and microenvironmental regulators of breast cancer metastasis
Andrew Ewald, Ph.D.
Johns Hopkins University

A Pan-Cancer Therapy-Resistance Mechanism via a Ferroptosis-Vulnerable Cell State
Stuart Schreiber, Ph.D.
Harvard University

Signaling network analysis reveals therapeutic targets and resistance mechanisms
Forest White, Ph.D.
Massachusetts Institute of Technology

Wrap-up Discussion; Summary of series and exploring potential for collaboration between the consortiums